Search Results - oncology

67 Results

Sort By:

Anti-LILRB5 Monoclonal Antibodies for Therapeutic and Diagnostic Use

Tumor microenvironment (TME) plays a critical role in regulating immune responses to tumors. UTHealth Houston and UTSW researchers discovered certain membrane tyrosine kinase Eph receptors, including EphA7 and EphB1, specifically bind to the immune inhibitory receptors leukocyte Ig-like receptor family B 5 (LILRB5) and result in bi-directional signaling....

Published: 3/4/2026 | Inventor(s):

Keywords(s):

Category(s): Diagnostics, Therapeutics, Oncology

Anti-LILRB1 Monoclonal Antibodies for Therapeutic and Diagnostic Use

LILRB1 expression on myeloid cells regulates both innate and adaptive immune responses. Researchers at UTHealth Houston and UTSW developed novel agonistic anti-LILRB1 monoclonal antibodies (mAbs) for autoimmune and inflammatory disease treatments, and novel antagonistic anti-LILRB1 mAbs for cancer immunotherapies. Background LILRB1, a member of the...

Published: 3/4/2026 | Inventor(s):

Keywords(s):

Category(s): Diagnostics, Therapeutics, Oncology

Anti-LAIR1 Monoclonal Antibodies for Therapeutic and Diagnostic Use

Leukocyte associated immunoglobulin like receptor 1 (LAIR1 or CD305) is an immune inhibitory receptor expressing on most immune cell types. Researchers at UTHealth Houston and UTSW generated novel antagonistic anti-LAIR1 monoclonal antibodies (mAbs) that inhibited the activity of immunosuppressive myeloid cells and reactivated T cells from cancer patients...

Published: 3/4/2026 | Inventor(s):

Keywords(s):

Category(s): Diagnostics, Therapeutics, Oncology

Anti-LILRB3 Monoclonal Antibodies for Therapeutic and Diagnostic Use

UTHealth Houston and UTSW researchers discovered that LILRB3 stimulates NF-κB signaling and enhances acute myeloid leukemia (AML) cells. They generated a panel of novel anti-LILRB3 monoclonal antibodies (mAbs), which exhibited increasing killing of leukemia cells and promoting cytotoxic T cell activity against tumors. Background Leukocyte immunoglobulin-like...

Published: 3/4/2026 | Inventor(s):

Keywords(s):

Category(s): Diagnostics, Oncology, Therapeutics

CAR-T Cells Targeting LILRB4 for Therapeutic and Diagnostic Use

CAR-T cell therapy development for AML has been limited by lack of an antigen with high specificity for AML cells that is not present on normal hematopoietic stem cells. UTHealth Houston and UTSW researchers discovered that leukocyte immunoglobulin-like receptor-B4 (LILRB4) is a tumor-associated antigen highly expressed on monocytic AML cells. They...

Published: 3/4/2026 | Inventor(s):

Keywords(s):

Category(s): Cell Therapies, Biologics, Oncology, Therapeutics

SLC13A3 Monoclonal Antibody for Therapeutic and Diagnostic Use

Description: SLC13A3 is revealed here, for the first time based on our evaluation, as a transporter for itaconate in tumor cells which plays a role in promoting tumor ferroptosis resistance, thereby weakening tumor immunity and immune checkpoint blockade (ICB). World renowned immuno-oncology leaders from UTHealth and University of Michigan (UMich)...

Published: 1/15/2026 | Inventor(s):

Keywords(s):

Category(s): Therapeutics, Oncology

Novel tasquinimod analogs having novel anticancer activity

Project ID: TECH-2025-31 Background Disruption of microtubules has dramatic effects on cell division due to the essential role they play in conjunction with the mitotic spindles during this process. Molecules that disrupt microtubule function are currently in widespread clinical use in cancer treatment. Taxanes, vinca alkaloids, and epothilones are...

Published: 10/2/2025 | Inventor(s): Ghassan Abushaikha, William Taylor

Keywords(s):

Category(s): Oncology

PTH1R PROTAC

Project ID: TECH-2025-20 Background Every 16 mins a man will die of Prostate cancer. Bone metastasis is the predominant cause of morbidity and mortality in prostate cancer, with > 80 % of lethal cases exhibiting skeletal involvement. Parathyroid hormone-related protein (PTHrP), secreted by tumor cells, binds and activates PTH1R on osteoblasts and...

Published: 2/12/2026 | Inventor(s): Xiaohong Li, Shang Su, Tim (Qingbin) Cui, Jian-Ting Zhang

Keywords(s):

Category(s): Oncology

Confederated C Prime Agents vs Cancers (PDAC) & Metabolic Disorders

Project ID: D2020-28 Background Based upon the success of a mixture of simvastatin (SIM) + metformin (Met) + digoxin (Dig), dubbed “C3”, for treating pancreatic ductal adenocarcinoma (PDAC) via a pleiotropic mechanism where attenuation of the BIRC5 pathway is a major component, we have pursued novel, single-molecular constructs that combine...

Published: 6/4/2025 | Inventor(s): Paul Erhardt, Shi-He Liu, F. Charles Brunicardi, Divya Andy

Keywords(s):

Category(s): Oncology

Analogs of peroxisome proliferator activated receptor (PPAR) agonists, and methods of using the same

Novel PPARδ Agonists for Bone Growth Background Osteoporosis is a silent disease of bones that affects tens of millions of people over the age of 50 with direct medical costs of over $31 billion yearly due to injuries from falls. With the aging population of the US there is a serious need for effective treatments to combat bone loss. There are...

Published: 2/12/2026 | Inventor(s): Bruce Heck, Paul Erhardt, Brian Kress, DongHyun Kim

Keywords(s):

Category(s): Long Bone/Joint Repair, Oncology

1 2 3 4 5 6 7